Dr. Brosnan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4805 NE Glisan St
Ste 11N
Portland, OR 97213Phone+1 503-215-1350
Education & Training
- University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2016 - 2019
- University of Colorado School of Medicine Anschutz Medical CampusClass of 2013
Certifications & Licensure
- OR State Medical License 2019 - 2025
- NC State Medical License 2016 - 2019
- NH State Medical License 2013 - 2017
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer Start of enrollment: 2021 Sep 10
Publications & Presentations
PubMed
- 40 citationsGalunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.Tomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X Kiely
The Lancet. Oncology. 2022-09-01 - 82 citationsUnderstanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies.Evelyn M. Brosnan, Carey K. Anders
Annals of Translational Medicine. 2018-05-15 - 19 citationsCrizotinib Effects on Creatinine and Non-Creatinine–Based Measures of Glomerular Filtration RateD. Ross Camidge, Evelyn M. Brosnan, Chamath DeSilva, Phillip J. Koo, Michel Chonchol
Journal of Thoracic Oncology. 2014-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: